| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447414 | European Journal of Cancer | 2011 | 6 Pages |
Abstract
The combination of sirolimus and bevacizumab at full doses is tolerable in the majority of patients. The availability and cost of sirolimus compared with other mTOR inhibitors make this an attractive agent to combine with bevacizumab.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
E.E.W. Cohen, M.R. Sharma, L. Janisch, M. Llobrera, L. House, K. Wu, J. Ramirez, G.F. Fleming, W.M. Stadler, M.J. Ratain,